Co-Founder
CurrentVasarya Therapeutics is developing targeted treatments for fibrotic disorders. Our novel therapeutic paradigm targets proteins that are only exposed in fibrotic tissue, allowing for inhibition of disease progression while avoiding toxicity associated with current, systemic standard of care therapies. My responsibilities and achievements as co-founder include:- Co-inventor of Vasarya's core anti-fibrotic targeting technology- Co-author of several successful grant applications totaling over $700k in non-dilutive funding- Lead investor relations and external partnerships- Coordinate between R&D and executive teams